2,3,7,8-Tetrachlorodibenzo-p-dioxin Causes an Extensive Alteration of 17 Beta-estradiol Metabolism in MCF-7 Breast Tumor Cells
Overview
Affiliations
MCF-7 breast tumor cells form multicellular foci in vitro when supplemented with 17 beta-estradiol (E2). In the presence of E2 and the aryl hydrocarbon-receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), MCF-7 cells grow to confluence but do not form foci. To investigate the role of E2 metabolism in this antiestrogenic effect of TCDD, analyses were performed by capillary GC/MS. The results revealed that pretreatment of MCF-7 cultures with TCDD (10 nM) rapidly depletes E2. In untreated cultures supplemented with 10 nM E2, the concentration of free E2 decreased to 4 nM in the first 12 hr, followed by a slower rate of decline. After 3 days most E2 in the medium was in conjugated form(s); 1.7 nM was present as free E2, and 2.9 nM was released by treatment with glucuronidase/sulfatase. In TCDD-treated cultures, E2 declined to 290 pM in 12 hr and after 2 days was not detected (less than 100 pM) either as free steroid or after treatment with glucuronidase/sulfatase. Intracellular E2 and estrone were likewise depleted by pretreatment with TCDD. Microsomes from TCDD-treated cells showed highly elevated aryl hydrocarbon-hydroxylase activity and catalyzed hydroxylations of E2 at C-2, C-4, C-15 alpha, and C-6 alpha with a combined rate of 0.85 nmol/min per nmol of cytochrome P-450 at saturating E2. These results suggest that depletion of E2 by enhanced metabolism accounts for the antiestrogenic activity of TCDD in MCF-7 cells.
Adipose Tissue as a Site of Toxin Accumulation.
Jackson E, Shoemaker R, Larian N, Cassis L Compr Physiol. 2017; 7(4):1085-1135.
PMID: 28915320 PMC: 6101675. DOI: 10.1002/cphy.c160038.
Mallozzi M, Leone C, Manurita F, Bellati F, Caserta D Int J Environ Res Public Health. 2017; 14(3).
PMID: 28327540 PMC: 5369169. DOI: 10.3390/ijerph14030334.
Brauze D, Zawierucha P, Kiwerska K, Bednarek K, Oleszak M, Rydzanicz M Mol Cell Biochem. 2016; 425(1-2):59-75.
PMID: 27796684 PMC: 5225230. DOI: 10.1007/s11010-016-2862-3.
The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy.
Powell J, Goode G, Eltom S J Cancer Ther. 2014; 4(7):1177-1186.
PMID: 25068070 PMC: 4111475. DOI: 10.4236/jct.2013.47137.
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.
Safe S, Lee S, Jin U Toxicol Sci. 2013; 135(1):1-16.
PMID: 23771949 PMC: 3748760. DOI: 10.1093/toxsci/kft128.